S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

Detalles Bibliográficos
Autores principales: Ayala, Rosa, Lopez, Nieves, Abulafia, Adi Shacham, Alwan, Maan, Yannakou, Costas K., Raman, Indu, Ribrag, Vincent, Fong, Chun Yew, Volchek, Yulia, Bonifacio, Massimiliano, Tucci, Alessandra, Kiladjian, Jean-Jacques, Rivas, Jésus Marïa Hernandez, Xicoy, Blanca, Al-Ali, Haifa Kathrin, Ianotto, Jean-Christope, Lee-Hoeflich, Si Tuen, Das, Sharmilla, Wu, Bin, Ravindran, Palanikumar, Zhao, Qian, Wang, Guan, Esposito, Oriana, Liu, Yu, Nikolova, Zariana, Tehlirian, Christopher, Coker, Shodeinde, Lavie, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428227/
http://dx.doi.org/10.1097/01.HS9.0000967764.47851.65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428227/
http://dx.doi.org/10.1097/01.HS9.0000967764.47851.65

Ejemplares similares